Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

For his DC-PGE project (DNA-binding domain Conditioned Precision Genome Editing), Prof. Frank Buchholz has been awarded an Advanced Grant from the European Research Council (ERC), the highest endowed ...

A groundbreaking method developed in Denmark could give thousands worldwide the answer they never thought they’d get. The ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

One way would be to ensure there is a consistent and predictable yield year by year. For two years in a row, beginning in the ...

Scientific breakthroughs have had life-changing effects on our nation's health and economy. Now is not the time to slash ...

There may be hopeful news ahead for families with a history of breast and ovarian cancer. Researchers from the University of ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by ...